{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:04:22Z","timestamp":1784811862389,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmic Physiol. Opt."],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s44402-026-00117-0","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:47:33Z","timestamp":1781185653000},"page":"896-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Outcomes and Predictors of Stepwise Atropine Concentration Adjustment in Paediatric Myopia Management"],"prefix":"10.1007","volume":"46","author":[{"given":"Sun Young","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Hae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"117_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036\u201342. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.006.","journal-title":"Ophthalmology"},{"key":"117_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2017.09.004","volume":"62","author":"IG Morgan","year":"2018","unstructured":"Morgan IG, French AN, Ashby RS, Guo X, Ding X, He M, et al. The epidemics of myopia: aetiology and prevention. Prog Retin Eye Res. 2018;62:134\u201349. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.09.004.","journal-title":"Prog Retin Eye Res"},{"key":"117_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/OPX.0000000000000516","volume":"92","author":"CW Pan","year":"1015","unstructured":"Pan CW, Dirani M, Cheng CY, Wong T, Saw S. The age-specific prevalence of myopia in Asia: a meta-analysis. Optom Vis Sci. 1015;92:258\u201366. https:\/\/doi.org\/10.1097\/OPX.0000000000000516.","journal-title":"Optom Vis Sci"},{"key":"117_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1475-1313.2005.00298.x","volume":"25","author":"SM Saw","year":"2005","unstructured":"Saw SM, Gazzard G, Shih-Yen EC, Chua W. Myopia and associated pathological complications. Ophthalmic Physiol Opt. 2005;25:381\u201391. https:\/\/doi.org\/10.1111\/j.1475-1313.2005.00298.x.","journal-title":"Ophthalmic Physiol Opt"},{"key":"117_CR5","doi-asserted-by":"publisher","first-page":"e0213714.","DOI":"10.1371\/journal.pone.0213714","volume":"14","author":"EK Kim","year":"2019","unstructured":"Kim EK, Park HL, Park CK. Posterior scleral deformations around optic disc are associated with visual field damage in open-angle glaucoma patients with myopia. PLoS ONE. 2019;14:e0213714. https:\/\/doi.org\/10.1371\/journal.pone.0213714.","journal-title":"PLoS ONE"},{"key":"117_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ajo.2013.06.005","volume":"156","author":"CW Pan","year":"2013","unstructured":"Pan CW, Cheng CY, Saw SM, Wang JJ, Wong TY. Myopia and age-related cataract: a systematic review and meta-analysis. Am J Ophthalmol. 2013;156:1021\u201333.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.06.005.","journal-title":"Am J Ophthalmol"},{"key":"117_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","volume":"157","author":"TY Wong","year":"2014","unstructured":"Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157:9\u201325.e12. https:\/\/doi.org\/10.1016\/j.ajo.2013.08.010.","journal-title":"Am J Ophthalmol"},{"key":"117_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.survophthal.2019.10.001","volume":"65","author":"D Kaphle","year":"2020","unstructured":"Kaphle D, Atchison DA, Schmid KL. Multifocal spectacles in childhood myopia: Are treatment effects maintained? A systematic review and meta-analysis. Surv Ophthalmol. 2020;65:239\u201349. https:\/\/doi.org\/10.1016\/j.survophthal.2019.10.001.","journal-title":"Surv Ophthalmol"},{"key":"117_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/02713680590907256","volume":"30","author":"P Cho","year":"2005","unstructured":"Cho P, Cheung SW, Edwards M. The Longitudinal Orthokeratology Research in Children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res. 2005;30:71\u201380. https:\/\/doi.org\/10.1080\/02713680590907256.","journal-title":"Curr Eye Res"},{"key":"117_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/OPX.0000000000001873","volume":"99","author":"P Chamberlain","year":"2022","unstructured":"Chamberlain P, Bradley A, Arumugam B, Hammond D, McNally J, Logan NS, et al. Long-term effect of dual-focus contact lenses on myopia progression in children: a 6-year multicenter clinical trial. Optom Vis Sci. 2022;99:204\u201312. https:\/\/doi.org\/10.1097\/OPX.0000000000001873.","journal-title":"Optom Vis Sci"},{"key":"117_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2020.10834","volume":"324","author":"JJ Walline","year":"2020","unstructured":"Walline JJ, Walker MK, Mutti DO, Jones-Jordan LA, Sinnott LT, Giannoni AG, et al. Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children: the BLINK randomized clinical trial. JAMA. 2020;324:571\u201380. https:\/\/doi.org\/10.1001\/jama.2020.10834.","journal-title":"JAMA"},{"key":"117_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ajo.2023.11.025","volume":"260","author":"S D\u00edaz-G\u00f3mez","year":"2024","unstructured":"D\u00edaz-G\u00f3mez S, Burgos-Mart\u00ednez M, Sankaridurg P, Urkia-Solorzano A, Carballo-\u00c1lvarez J. Two-year myopia management efficacy of extended depth of focus soft contact lenses (MYLO) in Caucasian children. Am J Ophthalmol. 2024;260:122\u201331. https:\/\/doi.org\/10.1016\/j.ajo.2023.11.025.","journal-title":"Am J Ophthalmol"},{"key":"117_CR13","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jama.2015.10803","volume":"314","author":"M He","year":"2015","unstructured":"He M, Xiang F, Zeng Y, Mai J, Chen Q, Zhang J, et al. Effect of time spent outdoors at school on the development of myopia among children in China: a randomized clinical trial. JAMA. 2015;314:1142\u20138. https:\/\/doi.org\/10.1001\/jama.2015.10803.","journal-title":"JAMA"},{"key":"117_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ophtha.2007.12.019","volume":"115","author":"KA Rose","year":"2008","unstructured":"Rose KA, Morgan IG, Ip J, Kifley A, Huynh S, Smith W, et al. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008;115:1279\u201385. https:\/\/doi.org\/10.1016\/j.ophtha.2007.12.019.","journal-title":"Ophthalmology"},{"key":"117_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025% and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126:113\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029.","journal-title":"Ophthalmology"},{"key":"117_CR16","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, et al. Two-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: Phase 2 report. Ophthalmology. 2020;127:910\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.011.","journal-title":"Ophthalmology"},{"key":"117_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam JC, Zhang XJ, Zhang Y, Tang SM, Yip BHK, Kam KW, et al. Three-year clinical trial of Low-Concentration Atropine for Myopia Progression (LAMP) study: continued versus washout: Phase 3 report. Ophthalmology. 2022;129:308\u201321. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.002.","journal-title":"Ophthalmology"},{"key":"117_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","volume":"131","author":"XJ Zhang","year":"2024","unstructured":"Zhang XJ, Zhang Y, Yip BHK, Kam KW, Tang F, Ling X, et al. Five-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: Phase 4 report. Ophthalmology. 2024;131:1011\u201320. https:\/\/doi.org\/10.1016\/j.ophtha.2024.03.013.","journal-title":"Ophthalmology"},{"key":"117_CR19","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113:2285\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2006.05.062.","journal-title":"Ophthalmology"},{"key":"117_CR20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","volume":"116","author":"L Tong","year":"2009","unstructured":"Tong L, Huang XL, Koh AL, Zhang X, Tang DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009;116:572\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.020.","journal-title":"Ophthalmology"},{"key":"117_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1% and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119:347\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.031.","journal-title":"Ophthalmology"},{"key":"117_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","volume":"157","author":"A Chia","year":"2014","unstructured":"Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014;157:451\u20137.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.09.020.","journal-title":"Am J Ophthalmol"},{"key":"117_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","volume":"128","author":"R Saxena","year":"2021","unstructured":"Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, et al. Atropine for the treatment of childhood myopia in India: multicentric randomized trial. Ophthalmology. 2021;128:1367\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2021.01.026.","journal-title":"Ophthalmology"},{"key":"117_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/jamaophthalmol.2023.5467","volume":"142","author":"Y Li","year":"2024","unstructured":"Li Y, Yip M, Ning Y, Chung J, Toh A, Leow C, et al. Topical atropine for childhood myopia control: the atropine treatment long-term assessment study. JAMA Ophthalmol. 2024;142:15\u201323. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.5467.","journal-title":"JAMA Ophthalmol"},{"key":"117_CR25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/bjo-2023-324450","volume":"108","author":"R Saxena","year":"2024","unstructured":"Saxena R, Gupta V, Dhiman R, Joseph E, Agarkar S, Neena R, et al. Low-dose atropine 0.01% for the treatment of childhood myopia: a pan-India multicentric retrospective study. Br J Ophthalmol. 2024;108:588\u201392. https:\/\/doi.org\/10.1136\/bjo-2023-324450.","journal-title":"Br J Ophthalmol"},{"key":"117_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.879210","volume":"9","author":"MW Hsieh","year":"2022","unstructured":"Hsieh MW, Chang HC, Chen YH, Chien KH. Classification-based approaches to myopia control in a Taiwanese cohort. Front Med. 2022;9:879210. https:\/\/doi.org\/10.3389\/fmed.2022.879210.","journal-title":"Front Med"},{"key":"117_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/ICL.0000000000001154","volume":"51","author":"HR Yum","year":"2025","unstructured":"Yum HR, Han SY, Park SH, Shin SY. Synergistic effect of dual-focus soft contact lenses and 0.05% atropine on myopia control in children with rapidly progressing myopia. Eye Contact Lens. 2025;51:92\u20137. https:\/\/doi.org\/10.1097\/ICL.0000000000001154.","journal-title":"Eye Contact Lens"},{"key":"117_CR28","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.ophtha.2020.12.036","volume":"128","author":"FF Li","year":"2021","unstructured":"Li FF, Zhang Y, Zhang X, Yip BHK, Tang SM, Kam KW, et al. Age effect on treatment responses to 0.05%, 0.025% and 0.01% atropine: Low-Concentration Atropine for Myopia Progression study. Ophthalmology. 2021;128:1180\u20137. https:\/\/doi.org\/10.1016\/j.ophtha.2020.12.036.","journal-title":"Ophthalmology"},{"key":"117_CR29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/opo.13379","volume":"44","author":"NA Brennan","year":"2024","unstructured":"Brennan NA, Nixon AD, Cheng X, Bullimore MA. Can we really distinguish \u2018responders\u2019 from \u2018non-responders\u2019 to myopia control interventions?. Ophthalmic Physiol Opt. 2024;44:1363\u20137. https:\/\/doi.org\/10.1111\/opo.13379.","journal-title":"Ophthalmic Physiol Opt"},{"key":"117_CR30","doi-asserted-by":"publisher","first-page":"e0257480.","DOI":"10.1371\/journal.pone.0257480","volume":"16","author":"HR Yum","year":"2021","unstructured":"Yum HR, Park SH, Shin SY. Influence of coronavirus disease 2019 on myopic progression in children treated with low-concentration atropine. PLoS ONE. 2021;16:e0257480. https:\/\/doi.org\/10.1371\/journal.pone.0257480.","journal-title":"PLoS ONE"},{"key":"117_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2021.101475","volume":"45","author":"N Erdinest","year":"2022","unstructured":"Erdinest N, London N, Levinger N, Lavy I, Pras E, Morad Y. Decreased effectiveness of 0.01% atropine treatment for myopia control during prolonged COVID-19 lockdowns. Cont Lens Anterior Eye. 2022;45:101475. https:\/\/doi.org\/10.1016\/j.clae.2021.101475.","journal-title":"Cont Lens Anterior Eye"},{"key":"117_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/jop.2011.0027","volume":"27","author":"PC Wu","year":"2011","unstructured":"Wu PC, Yang YH, Fang PC. The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren. J Ocul Pharmacol Ther. 2011;27:461\u20136. https:\/\/doi.org\/10.1089\/jop.2011.0027.","journal-title":"J Ocul Pharmacol Ther"},{"key":"117_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96698-6","volume":"11","author":"MN Chuang","year":"2021","unstructured":"Chuang MN, Fang PC, Wu PC. Stepwise low concentration atropine for myopic control: a 10-year cohort study. Sci Rep. 2021;11:17857. https:\/\/doi.org\/10.1038\/s41598-021-96698-6.","journal-title":"Sci Rep"},{"key":"117_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10792-025-03625-z","volume":"45","author":"HR Yum","year":"2025","unstructured":"Yum HR, Park SH, Shin SY. Effectiveness of a split-dose, twice-daily low-dose atropine monocular treatment in children with anisometropia: a retrospective study. Int Ophthalmol. 2025;45:257\u201363. https:\/\/doi.org\/10.1007\/s10792-025-03625-z.","journal-title":"Int Ophthalmol"},{"key":"117_CR35","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","volume":"34","author":"JR Polling","year":"2020","unstructured":"Polling JR, Tan E, Driessen S, Loudon SE, Wong HL, van der Schans A, et al. A 3-year follow-up study of atropine treatment for progressive myopia in Europeans. Eye. 2020;34:2020\u201328. https:\/\/doi.org\/10.1038\/s41433-020-1122-7.","journal-title":"Eye"},{"key":"117_CR36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/ceo.14289","volume":"51","author":"E Usmani","year":"2023","unstructured":"Usmani E, Callisto S, Chan WO, Taranath D. Real-world outcomes of low-dose atropine therapy on myopia progression in an Australian cohort during the COVID-19 pandemic. Clin Exp Ophthalmol. 2023;51:775\u201380. https:\/\/doi.org\/10.1111\/ceo.14289.","journal-title":"Clin Exp Ophthalmol"},{"key":"117_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10978-3","volume":"12","author":"LC Lee","year":"2022","unstructured":"Lee LC, Hsieh MW, Chen YH, Chien KH. Characteristics of responders to atropine 0.01% as treatment in Asian myopic children. Sci Rep. 2022;12:7380. https:\/\/doi.org\/10.1038\/s41598-022-10978-3.","journal-title":"Sci Rep"},{"key":"117_CR38","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1089\/jop.2022.0036","volume":"38","author":"H Cho","year":"2022","unstructured":"Cho H, Seo Y, Han SH, Han J. Factors related to axial length elongation in myopic children who received 0.05% atropine treatment. J Ocul Pharmacol Ther. 2022;38:703\u20138. https:\/\/doi.org\/10.1089\/jop.2022.0036.","journal-title":"J Ocul Pharmacol Ther"},{"key":"117_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43569-x","volume":"13","author":"I P\u00e9rez-Flores","year":"2023","unstructured":"P\u00e9rez-Flores I, Mac\u00edas-Murelaga B, Multicenter Group of Atropine Treatment for Myopia Control (GTAM), Barrio-Barrio J. Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci Rep. 2023;13:16310. https:\/\/doi.org\/10.1038\/s41598-023-43569-x.","journal-title":"Sci Rep"},{"key":"117_CR40","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/aos.13964","volume":"97","author":"O P\u00e4rssinen","year":"2019","unstructured":"P\u00e4rssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmol. 2019;97:510\u201318. https:\/\/doi.org\/10.1111\/aos.13964.","journal-title":"Acta Ophthalmol"},{"key":"117_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49739-0","volume":"13","author":"HR Yum","year":"2023","unstructured":"Yum HR, Park SH, Shin SY. Longitudinal analysis of refraction and ocular biometrics in preschool children with early-onset high myopia. Sci Rep. 2023;13:22474. https:\/\/doi.org\/10.1038\/s41598-023-49739-0.","journal-title":"Sci Rep"},{"key":"117_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02635-0","volume":"22","author":"S Yu","year":"2022","unstructured":"Yu S, Du L, Ji N, Li B, Pang X, Li X, et al. Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial. BMC Ophthalmol. 2022;22:454. https:\/\/doi.org\/10.1186\/s12886-022-02635-0.","journal-title":"BMC Ophthalmol"},{"key":"117_CR43","doi-asserted-by":"publisher","first-page":"e0281816.","DOI":"10.1371\/journal.pone.0281816","volume":"18","author":"P Nucci","year":"2023","unstructured":"Nucci P, Lembo A, Schiavetti I, Shah R, Edgar DF, Evans BJW. A comparison of myopia control in European children and adolescents with Defocus Incorporated Multiple Segments (DIMS) spectacles, atropine and combined DIMS\/atropine. PLoS ONE. 2023;18:e0281816. https:\/\/doi.org\/10.1371\/journal.pone.0281816.","journal-title":"PLoS ONE"},{"key":"117_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3928\/01913913-20250124-01","volume":"62","author":"JA Koulalis","year":"2025","unstructured":"Koulalis JA, Nelis P, Cools W, Tezcan F, Kuijpers RW. The short-term effect of atropine 0.1% on the axial length and choroid of children treated for myopia progression prevention, measured by optical coherence tomography angiography. J Pediatr Ophthalmol Strabismus. 2025;62:265\u201370. https:\/\/doi.org\/10.3928\/01913913-20250124-01.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"117_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2021.12.014","volume":"237","author":"JC Yam","year":"2022","unstructured":"Yam JC, Jiang Y, Lee J, Li S, Zhang Y, Sun W, et al. The association of choroidal thickening by atropine with treatment effects for myopia: two-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study. Am J Ophthalmol. 2022;237:130\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2021.12.014.","journal-title":"Am J Ophthalmol"},{"key":"117_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/ICL.0000000000000990","volume":"49","author":"K Richdale","year":"2023","unstructured":"Richdale K, Skidmore KV, Tomiyama ES, Bullimore MA. Compounded 0.01% atropine\u2014What\u2019s in the bottle?. Eye Contact Lens. 2023;49:219\u201323. https:\/\/doi.org\/10.1097\/ICL.0000000000000990.","journal-title":"Eye Contact Lens"}],"container-title":["Ophthalmic and Physiological Optics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44402-026-00117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44402-026-00117-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44402-026-00117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:51:08Z","timestamp":1784811068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44402-026-00117-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1007\/s44402-026-00117-0","relation":{},"ISSN":["0275-5408","1475-1313"],"issn-type":[{"value":"0275-5408","type":"print"},{"value":"1475-1313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}